4.7 Article

Effect of novel leukemia mutations (K75E & E222K) on interferon regulatory factor 1 and its interaction with DNA: insights from molecular dynamics simulations and docking studies

期刊

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
卷 39, 期 14, 页码 5235-5247

出版社

TAYLOR & FRANCIS INC
DOI: 10.1080/07391102.2020.1784790

关键词

Cancer; leukemia; IRF-1; DNA; mutation; stability; interaction

资金

  1. Deanship of Scientific Research, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia [2019-162-AMSJ]

向作者/读者索取更多资源

IRF-1 functions as a tumor suppressor gene in cell proliferation and differentiation, with mutations potentially affecting its stability and interaction with DNA, leading to inhibition of cancer suppression. Understanding the molecular effects of IRF-1 can aid in designing drugs targeting IRF-1 associated cancers, with the goal of reactivating its function to treat leukemia.
Interferon regulatory factor 1 (IRF-1) plays a vital role in cell proliferation and cell differentiation by acting as a tumor suppressor gene and its role is linked to various types of cancers, including leukemia and pre-leukemia myelodysplasia. Mutations in the coding region of the IRF-1 are likely to influence the IRF-1 and its DNA binding affinity. The molecular mechanism of the DNA recognition with the IRF-1 protein upon mutations is still unknown. In this study, we have elucidated the structural and functional behavior of the wild-type and mutant (K75E and E222K) IRF-1 proteins and their corresponding molecular mechanisms with DNA recognition at the molecular level, using molecular dynamics simulations. Furthermore, we also applied the docking approach to examine the binding between the IRF-1 protein and DNA upon mutations. This study evidently explains that, due to mutations, the IRF-1 structure loses its stability and becomes more flexible than the wild-type protein. This structural loss might affect IRF-1-DNA interaction and lead to the inhibition of cancer suppression. Identifying the effects of IRF-1 at the molecular level will be beneficial for designing drugs for IRF-1 associated cancers. These drugs should be designed so that they can help reactivate the IRF-1 function, by increasing the transcriptional activity, to treat leukemia.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据